Singapore markets closed

Daré Bioscience, Inc. (DARE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3111-0.0009 (-0.29%)
As of 02:47PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.3120
Open0.3195
Bid0.3088 x 200
Ask0.0000 x 0
Day's range0.3020 - 0.3240
52-week range0.2700 - 1.0600
Volume291,295
Avg. volume669,651
Market cap31.291M
Beta (5Y monthly)1.21
PE ratio (TTM)N/A
EPS (TTM)-0.3500
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.67
  • GlobeNewswire

    Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

    Daré joins a nationwide network working to accelerate transformative health solutionsSAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). As an Investor Catalyst Hub spoke, Daré gains access to potential funding and fle

  • GlobeNewswire

    Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

    $22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré representing 50% of the future payments otherwise payable to XOMA Transaction allows Daré to focus on advancing Phase 3 first-in-category investigational products Ovaprene®, a potential first FDA-approved hormone-free intravaginal monthly contraceptive, and Sildenafil Cream, 3.6%, a potential fir

  • GlobeNewswire

    Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

    Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will